University of North Carolina Chapel Hill
Welcome,         Profile    Billing    Logout  
 70 Trials 
226 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Le, Linda Van
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NRG-GY026, NCT05256225: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Recruiting
2/3
525
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk
National Cancer Institute (NCI), NRG Oncology
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Carcinosarcoma
10/27
10/27
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
286
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/24
01/26
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NRG-GY028, NCT05538897: Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recruiting
1/2
96
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Megestrol Acetate, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone, 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone, BDH 1298, BDH-1298, Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace, SC 10363, SC-10363
National Cancer Institute (NCI), NRG Oncology
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
01/27
01/27
NCT06305299: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting
1
27
US
iC9-CAR.B7-H3 T cells, iC9-CAR.B7-H3 T, Cyclophosphamide, Cycloblastin, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
03/26
03/26
NCT04670068: Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Active, not recruiting
1
7
US
CAR.B7-H3, Chimeric antigen receptor T cells with B7.H3 molecular target, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan
UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Epithelial Ovarian Cancer
02/24
02/30
CAMPSTIM, NCT06449638: Modified Platform Trial Assessing Multiple CAMPs and SOC Vs SOC Alone in the Treatment of Hard-to-Heal DFUs

Recruiting
N/A
272
US
Standard of Care, Revita, Relese, Cogenex, Enverse
StimLabs, SerenaGroup, Inc.
Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
06/26
08/26
ELDERLY, NCT03065972: Hemodialysis in the Elderly (70yrs & Older)

Recruiting
N/A
270
US
Surgical fistula creation from patient's anatomy, Fistula, Surgical Graft implant, FDA approved graft (various manufacturers)
E. Peden, MD, The Methodist Hospital Research Institute
Kidney Disease, Kidney Failure, Chronic Kidney Disease
02/25
02/25
Sikich, Linmarie
LAP01, NCT03522168: Long-term Antipsychotic Pediatric Safety Trial

Completed
N/A
509
US
Risperidone, Risperdal, Aripiprazole, Abilify
Duke University, The Emmes Company, LLC
Weight, Body
11/23
11/23
Mann, John
NCT04155983: High Versus Low Adductor Canal Block

Recruiting
4
140
US
Ropivacaine, naropin
Carilion Clinic
Osteo Arthritis Knee
12/21
12/21
NCT03272399: Nutrition for Post-Traumatic Headache

Recruiting
2
300
US
Diet/nutrition intervention, High omega-3 versus high omega-6 dietary intervention
Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Fort Belvoir Community Hospital, Womack Army Medical Center, University of North Carolina, Chapel Hill, National Institutes of Health (NIH)
Post-Traumatic Headache Chronic Without Intractable Headache
03/22
03/22
Donaldson, Scott H
AEROW, NCT05248230: 4D-710 in Adult Patients with Cystic Fibrosis

Recruiting
1/2
40
US
4D-710
4D Molecular Therapeutics
Cystic Fibrosis Lung
12/26
01/30
NICE-CF, NCT05362344: Colorectal Cancer Screening in Cystic Fibrosis

Active, not recruiting
N/A
350
US
Stool tests, Stool-based Fecal Immunochemical Testing (FIT) test and Stool-based DNA test (Cologuard) test.
University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation
Cystic Fibrosis, Colorectal Cancer, Adenoma
03/25
06/25
NCT06504589: A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Recruiting
N/A
400
US
Nicole Hamblett, Washington University School of Medicine, Florida State University, University of North Carolina, Chapel Hill, University of Toronto, Cystic Fibrosis Foundation
Cystic Fibrosis
08/29
08/29
Shaheen, Nicholas
NCT06732388: Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Not yet recruiting
2
64
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Endoscopic Procedure, Endoscopic Examination, Endoscopy, ES, Itraconazole, Lozanoc, Oriconazole, R 51,211, Sporanox, Placebo Administration, Questionnaire Administration, Radiofrequency Ablation, Ablation, Radiofrequency, Radiofrequency Interstitial Ablation, RFA
National Cancer Institute (NCI)
Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma
01/28
01/28
NCT04939051: Obeticholic Acid for Prevention in Barrett's Esophagus

Recruiting
2
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Esophageal Biopsy, Biopsy of Esophagus, Esophagogastroduodenoscopy, EGD, Upper Endoscopy, Liver Ultrasonographic Elastography, Fibroscan, TE, Transient Elastography, VCTE, Vibration-Controlled Transient Elastrography, Obeticholic Acid, INT-747, Ocaliva, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Barrett Esophagus, Esophageal Adenocarcinoma
09/25
09/26
NCT03243734: trūFreeze® Palliative Esophageal Cancer

Completed
N/A
49
US
trūFreeze® System spray cryotherapy
US Endoscopy Group Inc.
Esophageal Cancer
07/22
03/24
NCT04316975: Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Completed
N/A
75
US
Study Driven Procurement of Biopsies, Research Biopsies
University of North Carolina, Chapel Hill, Interpace Diagnostics Corporation
Barretts Esophagus With Dysplasia, Intramucosal Adenocarcinoma
12/23
12/23
NCT06687603: Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

Not yet recruiting
N/A
800
US
EsoCheck, EsoGuard
Case Comprehensive Cancer Center
Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
09/28
09/29
BEECAB, NCT02427269: University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

Enrolling by invitation
N/A
1000
US
Specimen Collection
University of North Carolina, Chapel Hill
Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
05/25
05/25
ReBET, NCT03554356: Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

Recruiting
N/A
70
US
CryoBalloon Focal Ablation System
University of North Carolina, Chapel Hill, PENTAX of America, Inc., Johns Hopkins University
Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
12/26
12/26
SWAT-BE, NCT05530343: Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Recruiting
N/A
2298
US
Seattle protocol, WATS3D brushings
University of Colorado, Denver
Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
03/26
03/26
SURVENT, NCT05753748: Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Recruiting
N/A
680
US
Endoscopic Eradication Therapy
University of Colorado, Denver, Baylor University, University of North Carolina, Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
02/28
02/28
FBE, NCT00288119: Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Recruiting
N/A
2000
US
Balloon Capsule Device, Esophageal Sampling Device BESD-001, Endoscopy, EGD
Case Western Reserve University, University Hospitals Cleveland Medical Center, Washington University School of Medicine, Fred Hutchinson Cancer Center, University of Washington, Mercy Medical Center, Johns Hopkins University, Mayo Clinic, University of North Carolina, Chapel Hill, The Cleveland Clinic, University of Pennsylvania, Columbia University, VA Puget Sound Health Care System
Barrett's Esophagus, Esophageal Neoplasm
07/28
07/28
Farber, Mark O
stAAAble, NCT06001918: Nectero EAST System Clinical Study

Recruiting
2/3
400
US
Nectero EAST System
Nectero Medical, Inc.
Abdominal Aortic Aneurysm
03/27
12/29
NCT02396199: Zenith® p-Branch® Endovascular Graft Pivotal Study

Active, not recruiting
N/A
80
US
Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents, Endovascular graft, Endovascular stent, Stent-graft, Fenestrated graft
Cook Research Incorporated
Aortic Aneurysm Abdominal
04/21
04/25
NCT05004051: ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

Recruiting
N/A
200
Canada, US
ViTAA Analysis
ViTAA Medical Solutions
Abdominal Aortic Aneurysms
12/26
12/26
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms

Approved for marketing
N/A
US
GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aneurysm
 
 
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting
N/A
102
Europe, US
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
01/23
09/26
IMPROVE-AD, NCT06087029: IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Recruiting
N/A
1100
US
TEVAR, Guideline directed medical therapy and surveillance of dissection
Duke University, The University of Texas Health Science Center, Houston, State University of New York - Downstate Medical Center, Oregon Health and Science University, National Heart, Lung, and Blood Institute (NHLBI)
Type B Aortic Dissection
06/30
06/30
NCT01654133: Evaluation of Visceral Function Following Endovascular Aortic Aneurysm Repair Using Branched Stent- Grafts

Enrolling by invitation
N/A
645
US
Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft, Endovascular repair of thoracoabdominal aortic aneurysm, Endovascular repair of ascending/arch aortic aneurysm using branched stent graft, Endovascular repair of ascending/ arch aortic aneurysm
University of North Carolina, Chapel Hill, UNC Hospitals, Cook Group Incorporated
Aortic Aneurysm, Abdominal, Ascending Aorta Aneurysm, Aortic Arch Aneurysm
08/30
08/30
Burks, Wesley
Peanut OIT, NCT00598039: Peanut Oral Immunotherapy

Active, not recruiting
N/A
40
US
Peanut flour
University of North Carolina, Chapel Hill, University of Arkansas
Food Hypersensitivity
07/14
07/14
Brown, Kevin
PREVENTABLE, NCT04262206: Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Recruiting
4
20000
US
Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet
Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences
Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
12/26
12/26
NCT04722042: Place-based Mapping in EAS Listeners

Completed
N/A
39
US
place-based mapping, default mapping
University of North Carolina, Chapel Hill, National Institute on Deafness and Other Communication Disorders (NIDCD)
Cochlear Implant
07/24
07/24
GWAS, NCT01088217: Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
N/A
8000
US, RoW
National Jewish Health, University of Colorado, Denver, Vanderbilt University, Landspitali University Hospital
Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia
06/25
06/25
NCT04707885: Clinical Utility of Residual Hearing in the Cochlear Implant Ear

Recruiting
N/A
40
US
Electrocochleography, ECochG
Ohio State University, National Institute on Deafness and Other Communication Disorders (NIDCD)
Hearing Loss, Sensorineural, Hearing Loss, Hearing Loss, Bilateral
12/26
12/27
NCT04506853: Single-Sided Deafness and Asymmetric Hearing Loss

Recruiting
N/A
65
Canada, US
MED-EL Cochlear Implant System
Med-El Corporation
Hearing Loss, Unilateral, Hearing Loss, Sensorineural
09/26
09/26
PAS-SSD, NCT05318417: Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness

Recruiting
N/A
60
US
The Cochlear™ Nucleus® Cochlear Implant (CI) System
Cochlear, NAMSA
Hearing Loss, Unilateral, Deafness, Unilateral
05/27
06/27
NCT05775367: Cochlear Implants in Young Children With SSD

Recruiting
N/A
60
US
Cochlear Implant, MED-EL SYNCHRONY 2 Cochlear Implant
University of North Carolina, Chapel Hill, Med-El Corporation
Single Sided Deafness, Unilateral Deafness, Hearing Loss, Unilateral, Hearing Loss, Congenital Hearing Loss, Deafness One Ear
05/30
05/30
Gay, Cynthia
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Completed
1
24
US
MGD020, MGD014
MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
05/24
05/24
HVTN143, NCT05959707: Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants

Suspended
1
77
RoW
VRC01.23LS, PGT121.414.LS, PGDM1400LS
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
01/25
01/25
Bulik, Cynthia
EDGI, NCT04378101: Eating Disorders Genetics Initiative

Completed
N/A
17991
US, RoW
Eating disorder diagnosis group
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH), University of Otago, University of Aarhus, QIMR Berghofer Medical Research Institute
Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder
05/23
05/23
ARFID-GEN, NCT05605067: Genetic Architecture of Avoidant/Restrictive Food Intake Disorder

Completed
N/A
5076
US
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH), Psychiatric Center Ballerup
ARFID, Eating Disorders, Eating Disorders in Children, Eating, Picky
08/24
08/24
EDGI2, NCT06594913: Eating Disorders Genetics Initiative 2

Recruiting
N/A
20000
Europe, US, RoW
Eating disorder diagnosis group
University of North Carolina, Chapel Hill, Queensland Institute of Medical Research, Karolinska Institutet, National Institute of Mental Health (NIMH), University of Otago, University of Aarhus, Yale University, Comenzar de Nuevo A.C., University of Sydney
Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Avoidant Restrictive Food Intake Disorder
08/27
08/27
Zucker, Nancy
NCT05105308: Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)

Active, not recruiting
N/A
203
US
Family Assisted Diet (FAD), FAD, Feeling and Body Investigator_ARFID Division (FBI-ARFID), FBI-ARFID
Duke University, National Institute of Mental Health (NIMH)
ARFID, Picky Eating, Eating Disorders in Children
02/25
02/25
Sanoff, Hanna
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting
3
120
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
06/27
06/27
CABINET, NCT03375320: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Hourglass Feb 2020 - Dec 2020 : Data from CABINET trial for advanced NET
Active, not recruiting
3
298
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Carcinoid Tumor, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
08/23
11/25
COBRA, NCT04068103: Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Active, not recruiting
2/3
1408
Canada, US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting
NRG Oncology, National Cancer Institute (NCI)
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
06/23
04/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
JANUS, NCT05610163: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

Recruiting
2
312
US
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC V8, Stage III Rectal Cancer AJCC V8
09/25
09/32
LCCC1717, NCT03446157: Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Active, not recruiting
2
24
US
Cetuximab, Erbitux, Palbociclib, Ibrance
UNC Lineberger Comprehensive Cancer Center, Amgen, Pfizer
Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer, Neoplasms, Colonic
05/23
01/26
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
NCT03454035: Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Recruiting
1
45
US
Ulixertinib, BVD-523, Palbociclib, Ibrance
UNC Lineberger Comprehensive Cancer Center, BioMed Valley Discoveries, Inc, Pfizer
Tumor, Solid, Pancreatic Cancer, Melanoma
08/25
11/26
McRee, Autumn
NCT03783936: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Completed
2
18
US
Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Ashwin Somasundaram, EMD Serono, University of North Carolina, Chapel Hill
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
09/20
08/22
NCT03442569: PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Active, not recruiting
2
56
US
Panitumumab, Vectibix, Nivolumab, Opdivo, Ipilimumab, Yervoy
UNC Lineberger Comprehensive Cancer Center, Amgen, Bristol-Myers Squibb
Colon Cancer
09/20
12/24
NCT04386057: LY3214996 +/- HCQ in Pancreatic Cancer

Completed
2
52
US
Hydroxychloroquine Sulfate, Plaquenil®), HCQ, LY3214996
Kimberly Perez, MD, Eli Lilly and Company
Pancreatic Cancer, Advanced Cancer
08/23
02/24
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Kim, Edwin
OUtMATCH, NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Hourglass Jul 2023 - Dec 2023 : Data readout from P3 OUtMATCH trial for food allergy
Active, not recruiting
3
471
US
Omalizumab, Xolair®, Placebo for Omalizumab, Placebo, Multi-Allergen Oral Immunotherapy, Multi-Allergen OIT, Placebo for Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen OIT, Double-Blind Placebo-Controlled Food Challenge Based Treatment, DBPCFC Based Treatment
National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc.
Peanut Allergy, Multi-food Allergy
03/23
06/25
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting
1/2
192
Canada, US
Peanut SLIT-tablet, Placebo
ALK-Abelló A/S, Parexel
Peanut Allergy
01/26
02/26
SUNBEAM, NCT04798079: Systems Biology of Early Atopy

Recruiting
N/A
2500
US
National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc.
Allergic Diseases, Food Allergy, Atopic Dermatitis
09/28
09/28
Frohlich, Flavio
NCT05086172: Ultrabrief Behavioral Activation for Reducing Alcohol Use

Completed
N/A
40
US
Ultrabrief Behavioral Activation, UBA
University of North Carolina, Chapel Hill
Alcohol Use Disorder, Mild, Alcohol Use Disorder, Moderate
05/23
05/23
DEBRA, NCT05084924: Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia

Completed
N/A
35
US
Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
Major Depressive Disorder, Anhedonia
07/23
07/23
NANCY, NCT05593965: Causal Role of Frontostriatal Circuitry in Goal-directed Behavior

Completed
N/A
24
US
Delta-beta TMS, Theta-gamma TMS, Arrhythmic TMS
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
Executive Function
07/23
07/23
ABBA, NCT05693922: Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression

Completed
N/A
28
US
Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation, Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
University of North Carolina, Chapel Hill, Foundation of Hope, North Carolina
Major Depressive Disorder
05/24
05/24
NCT03111290: Modulating Oscillations and Working Memory in Patients With Subdural Electrodes

Enrolling by invitation
N/A
30
NA
Direct Cortical Stimulation, Direct Cortical Stimulation Sham
University of North Carolina, Chapel Hill, National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH)
Working Memory, Epilepsy
01/26
01/26
STAR, NCT05204381: Theta Connectivity in Working Memory

Completed
N/A
71
US
Theta-frequency near-zero phase lag stimulation, Theta-frequency anti-synchrony stimulation, Arrhythmic near-zero phase lag stimulation, Arrhythmic independent stimulation, Alpha-frequency near-zero phase lag stimulation, Alpha-frequency anti-synchrony stimulation
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
Executive Function
12/24
12/24
NCT05907707: Effects of Gamma-tACS on Memory and Sleep

Completed
N/A
11
US
Gamma transcranial alternating current stimulation, DC-STIMULATOR MC Stimulator Plus, Control transcranial alternating current stimulation, EEG headband, ULTEEMNite, Actigraphy wristband
University of North Carolina, Chapel Hill
Transcranial Alternating Current Stimulation, Aging, Cognitive Decline, Memory, Sleep
12/23
12/23
K-BRAINED, NCT06012916: Brain Network Dynamics of Depression During Esketamine Treatment

Completed
N/A
8
US
Esketamine nasal spray, Spravato
University of North Carolina, Chapel Hill
Depressive Disorder, Major
08/24
08/24
NCT06252532: Causal Role of Top-Down Theta Oscillations in Prioritization

Enrolling by invitation
N/A
50
US
Direct cortical stimulation (DCS) Alpha, CereStim M96, Direct cortical stimulation (DCS) Theta, Sham Direct cortical stimulation (DCS), Direct cortical stimulation (DCS) In-Phase Theta, Direct cortical stimulation (DCS) Anti-Phase Theta
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
Working Memory, Epilepsy
01/26
01/26
NCT06696001: Neuroscience of Psychotherapy for Depression

Not yet recruiting
N/A
45
US
Psychoeducation, Behavioral Activation
University of North Carolina, Chapel Hill, Foundation of Hope, North Carolina
Depression
09/25
10/25
CARED, NCT06590038: Psychotherapy Feasibility Pilot of the Carolina Recovery From Depression Protocol

Not yet recruiting
N/A
15
US
Single Session Psychotherapy Intervention
University of North Carolina, Chapel Hill, The Foundation of Hope for Research and Treatment of Mental Illness
Depression, Unipolar
03/25
04/25
Schilling, Samantha
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting
3
360
Europe, US, RoW
Elamipretide, Elamipretide HCL, Placebo
Stealth BioTherapeutics Inc.
Age Related Macular Degeneration (ARMD)
08/26
08/27
PriCARE, NCT04110236: Pilot of Enhanced Child Adult Relationship Enhancement in Pediatric Primary Care

Completed
N/A
238
US
PriCARE, Child Adult Relationship Enhancement in Primary Care, Positive Discipline Module, PriCARE Positive Discipline Module
Children's Hospital of Philadelphia, Annie E. Casey Foundation, The Pew Charitable Trusts
Child Behavior Problem, Parent-Child Relations
06/22
08/22
NCT05233150: Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)

Recruiting
N/A
1932
US
PriCARE/CARIÑO, Child Adult Relationship Enhancement in Primary Care, Criando Niños con CARIÑO
University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Children's Hospital of Philadelphia
Parent-Child Relations, Child Maltreatment
07/27
07/27
Akulian, Jason
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
NCT06210685: The ACES Study for Aseptic Pleural Effusion

Recruiting
N/A
25
US
Automatic Continuous Effusion Shunt implantation, ACES Catheter
Pleural Dynamics, Inc., Medical Metrics Diagnostics, Inc
Pleural Effusion
06/25
12/25
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Recruiting
N/A
50
US
Observation
Tempus AI, AstraZeneca
Small Cell Lung Cancer
03/26
03/26
NCT05620329: UNC Pleural Fluid Registry

Recruiting
N/A
9999
US
UNC Lineberger Comprehensive Cancer Center
Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion, Empyema
01/50
01/50
Sanders, James O
CVBT, NCT04500041: Casting Vs Bracing for Idiopathic Early-Onset Scoliosis

Active, not recruiting
N/A
71
Europe, US, RoW
Casting, Bracing
University of Iowa, Orthopedic Research and Education Foundation, Pediatric Spine Study Group
Scoliosis Idiopathic, Early-Onset Scoliosis Deformity of Spine
01/26
01/26
sheikh, Saira
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Terminated
2
85
Europe, US, RoW
LY3361237, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus
12/23
12/23
NCT02633163: Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Recruiting
2
81
US
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Medical University of South Carolina
Systemic Lupus Erythematosus
08/25
02/26
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
LUPUS Brain, NCT04141046: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE

Terminated
N/A
4
US
XCSITE100 Stimulator - Individualized theta-tACS, XCSITE100 Stimulator - Individualized alpha-tACS, XCSITE100 Stimulator - Active Sham
University of North Carolina, Chapel Hill
Systemic Lupus Erythematosus, Depression
07/23
09/23
NCT05934149: Lupus Landmark Study: A Prospective Registry and Biorepository

Recruiting
N/A
3500
Canada, US
Lupus Research Alliance
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
12/33
12/33
Loeser, Richard
NCT05505552: Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:

Recruiting
N/A
50
US
Vitamin K, Phylloquinone, Placebo
Tufts University, University of North Carolina, Chapel Hill, Tufts Medical Center
Osteo Arthritis Knee
12/25
12/25
Jamieson, Katarzyna
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
A041703, NCT03739814: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting
2
64
US
Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Inotuzumab Ozogamicin, Besponsa, CMC 544, CMC-544, CMC544, Way 207294, WAY-207294
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
02/25
02/25
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Recruiting
2
300
US
Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
07/24
07/24
OPTIMIZE, NCT06001385: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Recruiting
2
190
US
Busulfan, Busulfex®, Fludarabine, Fludara®, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT, Post-Transplant Cyclophosphamide, Cytoxan®, PTCy, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient Reported Outcomes, PRO, Melphalan, Total-body irradiation, TBI, Cyclophosphamide
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
02/26
06/26
NCT04223765: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Recruiting
1
20
US
CAR.k.28, Kappa Chimeric Antigen Receptor and CD28 Endodomain, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan, Bendamustine, Bendeka, Treanda
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
03/28
03/43
Andermann, Tessa
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
07/24
 

Download Options